Drug reaction with eosinophilia and systemic symptoms

Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome) is caused by exposure to certain medications that may result in a rash, fever, inflammation of internal organs, lymphadenopathy, and characteristic hematologic abnormalities such as eosinophilia, thrombocytopenia, and atypical lymphocytosis. The syndrome has about a 10% mortality. Treatment consists of stopping the offending medication and providing supportive care. Systemic steroids are commonly used, as well, but no controlled clinical trials assess the efficacy of this treatment.

The term was coined in a 1996 report in an attempt to simplify terminology for a syndrome recognized as early as 1959.

DRESS is one of several terms that have been used to describe a severe idiosyncratic reaction to a drug that is characterized by a long latency of onset after exposure to the offending medication, a rash, involvement of internal organs, hematologic abnormalities, and systemic illness. Other synonymous names and acronyms include hypersensitivity syndrome (DIHS), anticonvulsant hypersensitivity syndrome, drug-induced hypersensitivity syndrome, drug-induced delayed multiorgan hypersensitivity syndrome, and drug-induced pseudolymphoma.

The symptoms of DRESS syndrome usually begin several weeks after exposure to the offending drug. No gold standard exists for diagnosis, and at least two diagnostic criteria have been proposed. The RegiSCAR criteria and the Japanese consensus group criteria are detailed in the table below.

Symptoms may be severe and involve many different organs. In a retrospective Taiwanese cohort study of 60 patients, these incidences were observed.

Drugs that commonly induce DRESS syndrome include phenobarbital, carbamazepine, phenytoin,lamotrigine, minocycline,sulfonamides, allopurinol,modafinil, dapsone, ziprasidone,vancomycin, and most recently olanzapine. It has been associated with HHV-6 reactivation.

...
Wikipedia